Shilpa Medicare gets EU initial approval for Rotigotine patch
SHILPAMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts less than Nifty Microcap 250 and 0.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Shilpa Medicare received Initial Authorization from Europe for Rotigotine transdermal patch (1,2,3,4,6,8 mg/24h), a generic version of Neupro for Parkinson's disease and Restless Legs Syndrome. European market opportunity is about USD 222 million. Company has on-boarded a commercialization partner in Europe, with targeted launch in FY27. First transdermal patch approval in Europe, made at Unit VI, Bengaluru.
Opens access to about USD 222 million European market, supports revenue growth from FY27.